OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
401758

Dr Soliman Abdel Kader Fakeeh Hospital Company SCJSC

Healthcare Facilities & ServicesVerified

The company maintains a relatively strong liquidity position, with a current ratio of 1.63, indicating that it has sufficient current assets to cover its current liabilities. However, the free cash flow is negative at -168.05 million SAR, which suggests that the company is investing heavily in capital expenditures, as evidenced by the -529.41 million SAR in capital expenditure. The negative net cash position, after subtracting total debt, raises some liquidity concerns. Profitability metrics show that the company is performing well relative to industry standards. The return on equity (ROE) is 9.15%, and the return on assets (ROA) is 4.98%, both of which are strong indicators of efficient use of equity and assets. The operating margin, calculated as operating income divided by revenue, is 9.97%, which is a healthy margin for a healthcare services provider. Geographically and segment-wise, the company's revenue is concentrated in its core healthcare services, with no disclosed segments or geographic breakdowns provided in the available data. This lack of diversification could pose a risk if the company's primary market experiences a downturn. The company's growth trajectory is positive, with a revenue of 3.09 billion SAR. While no specific growth rate is provided, the operating income of 307.999 million SAR and net income of 290.182 million SAR indicate a stable and profitable operation. The capital expenditures suggest that the company is investing in its infrastructure, which could support future growth. Risk factors include a medium liquidity risk, as highlighted by the negative free cash flow and the need for significant capital expenditures. The dilution risk is low, with no near-term pressure expected. The company's debt-to-equity ratio of 0.37 is relatively low, indicating a conservative capital structure. Recent events and filings do not provide specific details, but the company's financial health and operational performance suggest a stable outlook. The company's financials and risk profile are consistent with a healthcare services provider that is investing in its future while maintaining profitability.

30-day price · 4017+1.62 (+4.7%)
Low$33.84High$37.00Close$35.98As of21 May, 00:00 UTC
Profile
CompanyDr Soliman Abdel Kader Fakeeh Hospital Company SCJSC
Ticker4017.SE
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Dr Soliman Abdel Kader Fakeeh Hospital Company SCJSC operates in the healthcare sector, providing medical services and facilities, and generates revenue primarily through patient care and related healthcare services.

Classification. The company is classified under the Healthcare Facilities & Services industry within the Healthcare Services & Equipment business sector, with a classification confidence of 0.92.

The company maintains a relatively strong liquidity position, with a current ratio of 1.63, indicating that it has sufficient current assets to cover its current liabilities. However, the free cash flow is negative at -168.05 million SAR, which suggests that the company is investing heavily in capital expenditures, as evidenced by the -529.41 million SAR in capital expenditure. The negative net cash position, after subtracting total debt, raises some liquidity concerns. Profitability metrics show that the company is performing well relative to industry standards. The return on equity (ROE) is 9.15%, and the return on assets (ROA) is 4.98%, both of which are strong indicators of efficient use of equity and assets. The operating margin, calculated as operating income divided by revenue, is 9.97%, which is a healthy margin for a healthcare services provider. Geographically and segment-wise, the company's revenue is concentrated in its core healthcare services, with no disclosed segments or geographic breakdowns provided in the available data. This lack of diversification could pose a risk if the company's primary market experiences a downturn. The company's growth trajectory is positive, with a revenue of 3.09 billion SAR. While no specific growth rate is provided, the operating income of 307.999 million SAR and net income of 290.182 million SAR indicate a stable and profitable operation. The capital expenditures suggest that the company is investing in its infrastructure, which could support future growth. Risk factors include a medium liquidity risk, as highlighted by the negative free cash flow and the need for significant capital expenditures. The dilution risk is low, with no near-term pressure expected. The company's debt-to-equity ratio of 0.37 is relatively low, indicating a conservative capital structure. Recent events and filings do not provide specific details, but the company's financial health and operational performance suggest a stable outlook. The company's financials and risk profile are consistent with a healthcare services provider that is investing in its future while maintaining profitability.
Key takeaways
  • The company has a strong ROE of 9.15% and ROA of 4.98%, indicating efficient use of equity and assets.
  • The current ratio of 1.63 suggests a healthy liquidity position, but the negative free cash flow raises some concerns.
  • The company's capital expenditures are significant, indicating investment in future growth.
  • The debt-to-equity ratio of 0.37 is low, suggesting a conservative capital structure.
  • The company's liquidity risk is medium, and the dilution risk is low with no near-term pressure expected.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencySAR
Revenue$3.09B
Gross profit$703.9M
Operating income$308.0M
Net income$290.2M
R&D
SG&A
D&A
SBC
Operating cash flow$453.9M
CapEx-$529.4M
Free cash flow-$168.0M
Total assets$5.83B
Total liabilities$2.66B
Total equity$3.17B
Cash & equivalents$268.0M
Long-term debt$1.18B
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$3.17B
Net cash-$908.4M
Current ratio1.6
Debt/Equity0.4
ROA5.0%
ROE9.2%
Cash conversion1.6%
CapEx/Revenue-17.1%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 25 companies
Metric4017Activity
Op margin10.0%18.2% medp25 18.2% · p75 24.6%bottom quartile
Net margin9.4%14.7% medp25 11.7% · p75 28.1%bottom quartile
Gross margin22.8%19.7% medp25 19.7% · p75 39.8%above median
R&D / revenue24.3% medp25 6.6% · p75 24.3%
CapEx / revenue-17.1%4.9% medp25 4.2% · p75 6.3%bottom quartile
Debt / equity37.0%71.3% medp25 19.0% · p75 91.7%below median
Observations
IR observations
Mean price target41.94 SAR
Median price target44.00 SAR
High price target44.60 SAR
Low price target38.00 SAR
Mean recommendation2.83 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count1.00
Hold count5.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate1.52 SAR
Last actual EPS1.26 SAR
Source: analysis-pipeline (hybrid)Generated: 2026-05-24 16:34 UTCJob: d2d9fc49